Duchenne UK

MetrioPharm AG is a pharmaceutical development company based in Zurich, Switzerland, with research facilities in Berlin. Founded in 2007, the company focuses on creating therapies for chronic inflammatory diseases, including psoriasis, arthritis, and multiple sclerosis. Its lead product candidate, MP1032, is currently undergoing phase II clinical trials for the treatment of moderate to severe chronic plaque psoriasis. MetrioPharm aims to improve the effectiveness and tolerability of treatments for these conditions, addressing significant health risks posed by chronic diseases. Through its innovative approach, MetrioPharm seeks to halt the progression of inflammation-related diseases early and enhance the healthy lifespan of patients, thereby promoting better long-term health outcomes.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.